Respiratory Syncytial Virus Infections Clinical Trial
Official title:
A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY)
Verified date | September 2023 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the safety and tolerability of MEDI8897 compared to palivizumab when administered to preterm infants entering their first RSV season and children with chronic lung disease (CLD) and congenital heart disease (CHD) entering their first and second RSV season.
Status | Completed |
Enrollment | 925 |
Est. completion date | January 20, 2023 |
Est. primary completion date | May 3, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 0 Years to 1 Year |
Eligibility | Inclusion criteria 1. For the preterm cohort (excluding subjects with CLD or hemodynamically significant CHD): preterm infants in their first year of life and born = 35 weeks 0 days GA eligible to receive palivizumab in accordance with national or local guidelines, including those with: 1. Uncomplicated small atrial or ventricular septal defects or patent ductus arteriosus, or 2. Aortic stenosis, pulmonic stenosis, or coarctation of the aorta alone 2. For the CLD/CHD cohort: 1. Subjects with CLD - infants in their first year of life and a diagnosis of CLD of prematurity requiring medical intervention/management (ie, supplemental oxygen, bronchodilators, or diuretics) within the 6 months prior to randomization 2. Subjects with CHD - infants in their first year of life and documented, hemodynamically significant CHD (must be unoperated or partially corrected CHD) Note: Infants with hemodynamically significant acyanotic cardiac lesions must have pulmonary hypertension (= 40 mmHg measured pressure in the pulmonary artery) or the need for daily medication to manage CHD 3. Infants who are entering their first RSV season at the time of screening 4. Written informed consent and any locally required authorization (eg, Health Insurance Portability and Accountability Act in the USA, EU Data Privacy Directive in the EU) obtained from the subject's parent(s)/legal representative(s) prior to performing any protocol-related procedures, including screening evaluations 5. Subject's parent(s)/legal representative(s) able to understand and comply with the requirements of the protocol including follow-up and illness visits as judged by the investigator 6. Subject is available to complete the follow-up period, which will be 1 year after Season 1/ Dose 1 for subjects without CLD/CHD, or 1 year after Season 2/Dose 1 (or last replacement dose as applicable for CHD) for subjects with CLD/CHD Exclusion criteria 1. Any fever (= 100.4°F [= 38.0°C], regardless of route) or acute illness within 7 days prior to randomization 2. Any history of LRTI or active LRTI prior to, or at the time of, randomization 3. Known history of RSV infection or active RSV infection prior to, or at the time of, randomization 4. Hospitalization at the time of randomization, unless discharge is expected within the 7 days after randomization 5. Requirement for mechanical ventilation, extracorporeal membrane oxygenation, CPAP, or other mechanical respiratory or cardiac support at the time of randomization 6. Anticipated cardiac surgery within 2 weeks after randomization 7. Anticipated survival of < 6 months after randomization 8. Receipt of any investigational drug 9. Known renal impairment 10. Known hepatic dysfunction including known or suspected active or chronic hepatitis infection 11. Clinically significant congenital anomaly of the respiratory tract 12. Chronic seizure, or evolving or unstable neurologic disorder 13. Prior history of a suspected or actual acute life-threatening event 14. Known immunodeficiency, including human immunodeficiency virus (HIV) 15. Mother with HIV infection (unless the child has been proven to be not infected) 16. Any known allergy, including to immunoglobulin products, or history of allergic reaction 17. Receipt of palivizumab or other RSV mAb or any RSV vaccine, including maternal RSV vaccination 18. Receipt of any monoclonal or polyclonal antibody (for example, hepatitis B immune globulin, intravenous immunoglobulin) or anticipated use during the study 19. Any condition that, in the opinion of the investigator, would interfere with evaluation of the study drug or interpretation of subject safety or study results 20. Concurrent enrollment in another interventional study 21. Children of employees of the sponsor, clinical study site, or any other individuals involved with the conduct of the study, or immediate family members of such individuals |
Country | Name | City | State |
---|---|---|---|
Austria | Research Site | Graz | |
Belgium | Research Site | Bruxelles | |
Belgium | Research Site | Gent | |
Bulgaria | Research Site | Montana | |
Bulgaria | Research Site | Pazardzhik | |
Bulgaria | Research Site | Pleven | |
Bulgaria | Research Site | Plovdiv | |
Bulgaria | Research Site | Plovdiv | |
Bulgaria | Research Site | Ruse | |
Bulgaria | Research Site | Sliven | |
Bulgaria | Research Site | Sofia | |
Bulgaria | Research Site | Sofia | |
Bulgaria | Research Site | Veliko Tarnovo | |
Canada | Research Site | Edmonton | Alberta |
Canada | Research Site | Vancouver | British Columbia |
Czechia | Research Site | Praha 4 | |
Estonia | Research Site | Tallinn | |
Estonia | Research Site | Tartu | |
Finland | Research Site | Tampere | |
France | Research Site | Amiens Cedex 1 | |
France | Research Site | Bordeaux | |
France | Research Site | Brest | |
France | Research Site | Bron | |
France | Research Site | Caen | |
France | Research Site | Creteil Cedex | |
France | Research Site | Grenoble Cedex 9 | |
France | Research Site | Marseille | |
France | Research Site | Pau Cedex | |
Germany | Research Site | Frankenthal | |
Germany | Research Site | Leipzig | |
Germany | Research Site | Mannheim | |
Hungary | Research Site | Baja | |
Hungary | Research Site | Budapest | |
Hungary | Research Site | Debrecen | |
Hungary | Research Site | Kecskemét | |
Hungary | Research Site | Miskolc | |
Italy | Research Site | Pisa | |
Italy | Research Site | Verona | |
Japan | Research Site | Fukui-shi | |
Japan | Research Site | Fukuoka-shi | |
Japan | Research Site | Kitakyusyu-shi | |
Japan | Research Site | Maebashi-shi | |
Japan | Research Site | Saitama shi | |
Japan | Research Site | Setagaya-ku | |
Korea, Republic of | Research Site | Ansan-si | |
Korea, Republic of | Research Site | Seoul | |
Korea, Republic of | Research Site | Suwon-si | |
Latvia | Research Site | Jekabpils | |
Latvia | Research Site | Riga | |
Latvia | Research Site | Riga | |
Lithuania | Research Site | Kaunas | |
Lithuania | Research Site | Kaunas | |
Mexico | Research Site | Cuernavaca | |
Mexico | Research Site | Mexico | |
New Zealand | Research Site | Christchurch | |
Poland | Research Site | Bydgoszcz | |
Poland | Research Site | Gdansk | |
Poland | Research Site | Krakow | |
Poland | Research Site | Kraków | |
Poland | Research Site | Wroclaw | |
Russian Federation | Research Site | Kazan | |
Russian Federation | Research Site | Novosibirsk | |
Russian Federation | Research Site | Perm | |
Russian Federation | Research Site | Saint Petersburg | |
Russian Federation | Research Site | Saint Petersburg | |
Russian Federation | Research Site | St Petersburg | |
Russian Federation | Research Site | Yaroslavl | |
South Africa | Research Site | Cape Town | |
South Africa | Research Site | Cape Town | |
South Africa | Research Site | Johannesburg | |
South Africa | Research Site | Johannesburg | |
South Africa | Research Site | Pretoria | |
South Africa | Research Site | Pretoria | |
South Africa | Research Site | Soweto | |
Spain | Research Site | Alicante | |
Spain | Research Site | Boadilla del Monte | |
Spain | Research Site | Elche | |
Spain | Research Site | Leganes | |
Spain | Research Site | Lleida | |
Spain | Research Site | Madrid | |
Spain | Research Site | Malaga | |
Spain | Research Site | Pozuelo de Alarcon | |
Spain | Research Site | Sant Cugat del Valles | |
Spain | Research Site | Tarragona | |
Sweden | Research Site | Stockholm | |
Turkey | Research Site | Adana | |
Turkey | Research Site | Izmir | |
Turkey | Research Site | Kocaeli | |
Ukraine | Research Site | Chernivts? | |
Ukraine | Research Site | Dnipro | |
Ukraine | Research Site | Ivano-Frankivsk | |
Ukraine | Research Site | Kharkiv Region | |
Ukraine | Research Site | Odesa | |
Ukraine | Research Site | Sumy | |
Ukraine | Research Site | Vinnytsia | |
United Kingdom | Research Site | Leicester | |
United Kingdom | Research Site | London | |
United Kingdom | Research Site | Nottingham | |
United States | Research Site | Anaheim | California |
United States | Research Site | Atlanta | Georgia |
United States | Research Site | Aurora | Colorado |
United States | Research Site | Charlottesville | Virginia |
United States | Research Site | Chicago | Illinois |
United States | Research Site | Cincinnati | Ohio |
United States | Research Site | Colorado Springs | Colorado |
United States | Research Site | Columbia | Missouri |
United States | Research Site | Columbus | Ohio |
United States | Research Site | Corpus Christi | Texas |
United States | Research Site | Durham | North Carolina |
United States | Research Site | Greenville | North Carolina |
United States | Research Site | Greenville | South Carolina |
United States | Research Site | Indianapolis | Indiana |
United States | Research Site | Jackson | Mississippi |
United States | Research Site | Layton | Utah |
United States | Research Site | Long Beach | California |
United States | Research Site | Los Angeles | California |
United States | Research Site | Louisville | Kentucky |
United States | Research Site | Mineola | New York |
United States | Research Site | Morgantown | West Virginia |
United States | Research Site | National City | California |
United States | Research Site | Paramount | California |
United States | Research Site | Saint George | Utah |
United States | Research Site | Seattle | Washington |
United States | Research Site | South Bend | Indiana |
United States | Research Site | Syracuse | New York |
United States | Research Site | Washington | District of Columbia |
United States | Research Site | West Covina | California |
United States | Research Site | West Des Moines | Iowa |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
United States, Austria, Belgium, Bulgaria, Canada, Czechia, Estonia, Finland, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, New Zealand, Poland, Russian Federation, South Africa, Spain, Sweden, Turkey, Ukraine, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and Tolerability of MEDI8897 as Assessed by the Occurrence of All Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Special Interest (AESIs) and New Onset Chronic Disease (NOCD) | Safety and tolerability of MEDI8897 will be assessed by the occurrence of all treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (TESAEs) , adverse events of special interest (AESIs), and new onset chronic diseases (NOCDs) | 360 days post first dose | |
Secondary | Serum Concentrations of MEDI8897 and Palivizumab | Summary of individual MEDI8897 and palivizumab serum concentration data by treatment group along with descriptive statistics. | Day 15, Day 31, Day 151 post first dose in Season 1 and Season 2 | |
Secondary | Incidence of Anti-drug Antibody (ADA) to MEDI8897 and Palivizumab in Serum | Incidence of ADA to MEDI8897 and palivizumab as assessed by the percentage of participants with any post-baseline ADA positive by treatment group. | 360 days post first dose | |
Secondary | Incidence of Medically Attended Lower Respiratory Track Infection (LRTI) and Hospitalization Due to Reverse Transcriptase Chain Reaction (RT-PCR) Confirmed Respiratory Syncytial Virus (RSV) Through 150 Days Post First Dose | Incidence of medically attended LRTI (inpatient and outpatient) due to RT-PCR-confirmed RSV through 150 days after Dose 1 for season 1 and season 2. Incidence of LRTI hospitalizations due to RT-PCR-confirmed RSV through 150 days after Dose 1 for season 1 and season 2. | 150 days post first dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03698084 -
RESCEU: Defining the Burden of RSV Disease
|
||
Completed |
NCT04090658 -
A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults
|
Phase 1 | |
Completed |
NCT04231968 -
A Study of AK0529 in Chinese Infants Hospitalized With RSV
|
Phase 3 | |
Completed |
NCT03227029 -
Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age
|
Phase 1 | |
Terminated |
NCT02948127 -
Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age
|
Phase 1 | |
Withdrawn |
NCT02864628 -
RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.
|
Phase 1 | |
Completed |
NCT02873286 -
RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults
|
Phase 2 | |
Completed |
NCT02984280 -
Specific Respiratory Infections as Triggers of Acute Medical Events
|
N/A | |
Completed |
NCT02247726 -
RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.
|
Phase 2 | |
Completed |
NCT02040831 -
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
|
Phase 1 | |
Completed |
NCT02237209 -
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
|
Phase 1 | |
Completed |
NCT01915394 -
Respiratory Syncytial Virus Infection in Neonatal Intensive Care Units Throughout Turkey: Prospective Multicenter Study (TurkNICU-RSV Trial)
|
N/A | |
Completed |
NCT01355016 -
A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00232635 -
A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT
|
Phase 2 | |
Completed |
NCT01155193 -
Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany
|
||
Not yet recruiting |
NCT06083623 -
A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants
|
Phase 2/Phase 3 | |
Terminated |
NCT02890381 -
Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age
|
Phase 1 | |
Active, not recruiting |
NCT03422237 -
Evaluating the Infectivity, Safety, and Immunogenicity of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants and Children 6 to 24 Months of Age
|
Phase 1 | |
Completed |
NCT03674177 -
A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women
|
Phase 1 | |
Completed |
NCT01968083 -
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
|
Phase 1 |